Your session is about to expire
← Back to Search
Behavioral Intervention
E3 Diabetes Program for Type 2 Diabetes (E3Diabetes Trial)
N/A
Waitlist Available
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Patient has Type 1 Diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months and 12 months
Awards & highlights
No Placebo-Only Group
Summary
"This trial aims to reduce the difference in how well type 2 diabetes is managed between African American and Latinx patients at Rush University Medical Center clinics."
Who is the study for?
This trial is for African American and Latinx adults with uncontrolled Type 2 Diabetes (A1C level of 8.0 or higher in the past 3 months), who are patients at eligible Rush primary care clinics, have access to a cellphone, and are not enrolled in other remote diabetes programs.
What is being tested?
The study tests two approaches: one where patients work with an E3 Multidisciplinary Team, and another where they use E3 Self-Guided Education to manage their Type 2 Diabetes. The goal is to improve diabetes control among these groups.
What are the potential side effects?
Since this trial involves educational interventions rather than medications, traditional side effects like those seen with drugs aren't expected. However, participants may experience stress or time demands related to managing their condition.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have Type 1 Diabetes.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months and 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months and 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Hemoglobin A1C
Secondary study objectives
Diabetes Self Management
Health Care System Distrust
Medication Adherence
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Diabetes Team-Based GroupExperimental Treatment1 Intervention
A multidisciplinary team composed of a pharmacist, social worker, community health worker, and dietician will provide glucose monitoring, medication titration, diet education and reinforcement, and referrals for social needs. The pharmacist will remind patients to get A1C readings at 3 months and 6 months. The team will interact with the patients predominantly via tele-health remotely for 6 months.
Group II: Diabetes Self-Guided GroupActive Control1 Intervention
A registered nurse will ensure patients have glucose monitors and supplies on enrollment and will call to remind patients to obtain A1C readings at 3 months and 6 months. Patients will continue with standard clinical care for type 2 diabetes in addition to receiving timed, mailed educational materials on type 2 diabetes monitoring and diabetes diet and lifestyle recommendations for 6 months.
Find a Location
Who is running the clinical trial?
Rush University Medical CenterLead Sponsor
439 Previous Clinical Trials
250,096 Total Patients Enrolled
Novartis PharmaceuticalsIndustry Sponsor
2,921 Previous Clinical Trials
4,254,162 Total Patients Enrolled